Basic Stalevo Information

• INN (International Nonproprietary Name): Levodopa, Carbidopa, Entacapone.
• Brand Names Available In Canada (English): Stalevo (film-coated tablets) distributed under Novartis/Orion.
• ATC Code: N04BA03.
• Forms & Dosages: Film-coated tablets containing 200 mg entacapone with levodopa/carbidopa in the following strengths — Stalevo 50 (50 mg levodopa / 12.5 mg carbidopa), Stalevo 75 (75 mg levodopa / 18.75 mg carbidopa), Stalevo 100 (100 mg levodopa / 25 mg carbidopa), Stalevo 125 (125 mg levodopa / 31.25 mg carbidopa), Stalevo 150 (150 mg levodopa / 37.5 mg carbidopa), Stalevo 200 (200 mg levodopa / 50 mg carbidopa).
• Manufacturers In Canada (English): Distributed in Canada under Novartis and Orion Pharma brands.
• Registration Status In Canada (English): Stalevo is approved for Rx use in Canada by national regulatory authorities.
• OTC / Rx Classification: Prescription Only Medicine (Rx) in regulated markets including Canada.

Availability & Price Landscape

Where can patients find Stalevo in Canada and what should they expect about stock and cost?

Major national chains such as Shoppers Drug Mart, Rexall and London Drugs may stock branded Stalevo in blister packs but availability varies by store and province.

Some stores hold Stalevo routinely while others dispense it only on patient request or via special order from the distributor.

A provincial heatmap of store availability is useful for planning refill logistics, since urban outlets often restock faster than remote ones.

Online Canadian pharmacies list Stalevo but require a valid prescription and often follow stricter verification depending on provincial college rules.

Cross-border sourcing from the U.S. is common for price reasons but can introduce customs delays and products without a Canadian DIN.

Retail prices vary by package size and stock; expect higher prices at walk-in retail vs some licensed Canadian online pharmacies that offer competitive pricing.

Provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ may subsidize eligible patients, subject to formulary listing and special authorizations.

Price factors to consider include tablet strength, pack quantity and insurer coverage.

For convenience, this online pharmacy offers discreet delivery across Canada in 5-14 days, though legal classification as Rx-only still applies and pharmacies typically require verification.

Online Pharmacy Trends In Canada

How do online pharmacies handle prescriptions and what restrictions apply across provinces?

Licensed Canadian online pharmacies commonly list Stalevo for patients with an existing prescription and verify prescriptions against provincial rules.

Where provincial college policies require stricter verification, pharmacies may phone the prescriber or request original paperwork.

Cross-border importation from the United States is sometimes used by patients seeking lower retail prices, but those products may not carry a Canadian Drug Identification Number and can be delayed by customs.

Online ordering steps differ from in-store pickup and typically include prescription upload, pharmacist verification and shipping in original packaging.

In provinces with robust e-prescribing, turnaround may be faster than jurisdictions requiring paper forms.

Patients should confirm DIN matching and ensure the dispensing site is licensed in Canada to avoid authenticity concerns.

Choosing a pharmacy that clearly explains verification steps reduces risk of delayed deliveries or rejected packages at customs.

Price Ranges By Package Size

What influences the final out-of-pocket cost for Stalevo in Canada?

Prices vary widely by strength and pack size, with retail store prices typically higher than some online Canadian pharmacies.

Provincial formularies and special authorization requirements determine whether public plans cover Stalevo for a given patient.

Common price factors include strength (for example, Stalevo 100 vs Stalevo 200), quantity per box, and whether entacapone-containing combination is preferred by the prescriber.

Private insurance or seniors’ benefits may lower copays, while patients without coverage will see full retail rates.

Pharmacies may also offer savings on repeat deliveries or multi-pack orders for chronic therapy.

When switching from separate levodopa/carbidopa plus entacapone to a fixed combination, patients should check formulary rules since combination tablets can be treated differently by insurers.

Canadian Patient Insights & Satisfaction Levels

What are Canadian patients saying online about using Stalevo?

Conversations on Reddit communities such as r/Parkinsons and r/CanadaHealth, HealthBoards and local support-group forums highlight real-world concerns and benefits.

Forum posts often focus on medication timing, strategies to manage "wearing off", and occasional pharmacy supply issues that affect continuity of care.

Short, anonymized forum excerpts with dates can be helpful on product pages to reflect patient experience without identifying individuals.

Many Canadian patients report improved "on" time after switching from levodopa/DDCI regimens to Stalevo because entacapone is already included in every tablet.

Top benefits cited include reduced off time and simplified dosing compared with taking separate entacapone tablets with each levodopa dose.

Common challenges reported are emergence or worsening of dyskinesia, nausea, and the cosmetic issue of brownish urine discolouration.

Access can vary by region, with urban patients often reporting faster restock and rural patients encountering longer delays.

Reported Benefits And Challenges From Canadian Patients

Which outcomes should patients expect and what side effects are commonly discussed?

Patients who switch to Stalevo frequently describe smoother motor control and fewer short-duration off episodes during the day.

The presence of entacapone in every tablet helps prolong levodopa's effect and reduces fluctuation frequency for many users.

However, increased dyskinesia is commonly reported as a trade-off in some patients once levodopa exposure is prolonged.

Other typical adverse effects mentioned are nausea, insomnia and orthostatic dizziness, which usually require counselling or dose adjustment.

Patient satisfaction often hinges on balancing reduced off time with tolerability and cost or formulary access.

Product Overview & Brand Variants

What exactly is inside a Stalevo tablet and which brand variants appear in Canada?

The INN for the product is a triple combination: levodopa, carbidopa and entacapone.

In Canada the combination is marketed as Stalevo by Novartis or Orion and is supplied in brown, oval film-coated tablets across multiple strengths.

All tablet strengths contain a fixed 200 mg of entacapone alongside varying levodopa/carbidopa amounts.

Available strengths are Stalevo 50, 75, 100, 125, 150 and 200, with corresponding carbidopa components as specified in product monographs.

Product pages should display the Health Canada Drug Identification Number (DIN) and the current status for each marketed strength when available.

Legal Classification Under Health Canada

Is Stalevo prescription-only in Canada?

Yes — Stalevo is classified as a prescription-only medicine (Rx) in Canada according to national regulatory listings.

Each marketed strength carries a DIN which helps verify the product and its authorization status with Health Canada.

Product pages should include DIN lookup instructions and a link to the Health Canada database for consumer verification.

Indications In Local Canadian Medical Practice

For which patients is Stalevo typically prescribed in Canada?

Health Canada approves Stalevo for adults with Parkinson’s disease who experience motor fluctuations or "wearing off" despite standard levodopa/DDCI therapy.

When initiating Stalevo, prescribers generally match the patient’s current levodopa/DDCI dose to the closest Stalevo tablet and titrate to effect.

Specialist consultation with neurology or a movement disorder clinic is common for complex motor fluctuation cases or when planning a switch.

Off-label use is uncommon in Canada but clinicians may adjust regimens for simplification of polypharmacy or complex dosing schedules, with clear documentation.

Situations where a specialist may consider switching include inadequate control on current therapy, frequent severe off episodes, or patient preference for fewer tablets per dose.

How It Works In The Body

How does the combination of levodopa, carbidopa and entacapone improve symptoms?

Levodopa is converted to dopamine in the brain where it replaces the neurotransmitter lost in Parkinson’s disease.

Carbidopa is a DDC inhibitor that prevents peripheral conversion of levodopa, allowing more levodopa to reach the brain and reducing peripheral side effects like nausea.

Entacapone is a COMT inhibitor that slows peripheral breakdown of levodopa, prolonging its plasma half-life and smoothing motor fluctuations.

Because every Stalevo tablet contains 200 mg entacapone, the formulation increases central levodopa availability without requiring separate entacapone dosing.

Clinically this often translates into reduced off time and more consistent "on" periods for patients with motor fluctuations.

Key pharmacologic points are COMT inhibition, increased levodopa exposure and matching dose titration to prior levodopa/DDCI therapy.

Dosage & Administration

How is Stalevo normally started and adjusted in Canadian practice?

Initiation generally involves matching the patient’s current levodopa/DDCI dose to the nearest Stalevo tablet strength.

Maintenance dosing is commonly one tablet per dose taken three to seven times daily, tailored for symptom control.

The maximum recommended limit is not to exceed 200 mg levodopa per dose or 2,000 mg levodopa per day.

Elderly patients usually start at lower doses and are monitored closely for tolerability.

Renal impairment requires caution with monitoring for increased adverse events, and hepatic impairment may require dose reduction or avoidance because entacapone exposure increases.

Patients should be counselled on missed-dose instructions: take as soon as remembered but do not double up the next dose.

Contraindications & Side Effects

Who should not take Stalevo and what adverse effects require vigilance?

Absolute contraindications include hypersensitivity to components, narrow-angle glaucoma, severe liver disease and pheochromocytoma.

Relative contraindications include a history of severe cardiovascular disease, severe renal impairment and a history of psychosis, and caution with non-selective MAO inhibitors.

Common side effects are nausea, diarrhea, dyskinesia, urine discolouration, dizziness or orthostatic hypotension and insomnia.

Rare but serious events reported include severe liver injury signals, neuroleptic malignant‑like reactions, severe psychosis and arrhythmias in overdose situations.

Patients should be instructed to report red-flag symptoms such as sudden severe muscle rigidity, fever, altered consciousness, chest pain or sustained palpitations immediately.

Comparable Medicines In Canada

What are commonly used alternatives to Stalevo and when are they preferred?

Main comparators in Canada include Sinemet (levodopa/carbidopa), Madopar (levodopa/benserazide in some markets) and Comtan (entacapone as an adjunct).

Sinemet omits entacapone, which allows flexible addition of COMT inhibitors if needed, and may be preferred where entacapone dosing needs careful titration.

Comtan is used as the entacapone component when clinicians prefer separate titration of the COMT inhibitor.

Pros of Stalevo are simplified single-tablet dosing and automatic inclusion of entacapone to reduce off time.

Cons include less flexibility in entacapone titration, potential for increased dyskinesia and variability in formulary access and cost.

Choosing Stalevo versus separate components depends on the clinical goal of simplification, patient tolerance and insurance coverage.

Current Research & Trends

What do recent studies and clinic reports say about fixed combinations like Stalevo?

Recent literature from 2022–2025 has focused on long-term motor outcomes, dyskinesia management and quality-of-life comparisons between fixed combinations and separate dosing.

Across studies, combination tablets that include entacapone generally reduce off-time compared with levodopa/DDCI alone, but dyskinesia risk remains a trade-off.

Real-world data from movement disorder clinics in Canada suggest adherence benefits when patients move to single-tablet combinations.

Researchers continue to study personalized dosing strategies to balance smoother motor control with minimization of involuntary movements.

Common Patient Questions In Canada

Can my provincial plan cover Stalevo and what should I expect when starting it?

Coverage varies by province; Ontario Drug Benefit, BC PharmaCare and RAMQ each have specific formulary rules and may require special authorization for Stalevo.

Patients should check the provincial formulary, consult their neurologist and have the prescriber submit any required special-authority paperwork.

When starting Stalevo, patients can expect improved "on" time for many, alongside possible nausea or dyskinesia, and brownish urine as a harmless but noticeable effect.

Practical advice includes carrying an anti-nausea plan if previously affected, monitoring orthostatic symptoms and keeping a motor diary to track benefits and side effects.

Travel with Stalevo across provinces or to the U.S. is generally allowed when carrying a prescription and original packaging, but customs and cross-border rules warrant attention for imported products.

Regulatory Status

How was Stalevo approved and why is the DIN important?

Stalevo is approved as a prescription medicine in Canada after regulatory review that demonstrated efficacy for motor fluctuations and an acceptable safety profile.

The Drug Identification Number (DIN) identifies the marketed product in Canada and should appear on blister packs and pharmacy receipts.

Consumers are advised to check the DIN and verify it on Health Canada’s online database if authenticity or registration status is a concern.

If a discrepancy is found, contacting the manufacturer or the provincial drug regulatory body is recommended.

Visual Recommendations

What visuals improve patient understanding and conversion on product pages?

Recommended infographics include a tablet-strengths grid showing Stalevo 50–200 with levodopa/carbidopa component mg and the fixed 200 mg entacapone.

A mechanism flowchart showing how entacapone prolongs levodopa effect and reduces off time is useful for patient education.

Coverage maps highlighting provincial formulary notes for Ontario, BC and Quebec help set realistic expectations for subsidization.

Product photography should include high-resolution images of blister packs, close-ups of tablet markings and visible DIN labels.

Buying & Storage Advice

What tips help ensure timely access and correct storage of Stalevo in Canadian climates?

In-store buyers should call their local Shoppers Drug Mart, Rexall or London Drugs to confirm stock before going to pick up a prescription.

Online purchasers must ensure the pharmacy is licensed in Canada, verify prescription upload procedures and confirm that the DIN on the dispensed product matches Canadian records.

Be cautious about cross-border purchases that lack a DIN since customs may seize such shipments or delays may occur.

Store Stalevo below 30°C and protect it from moisture and light; in humid regions of Canada keep tablets in their original blister packs rather than transferring to pill organisers for long-term storage.

For travel, carry medication in original packaging with the prescription and avoid leaving packs in a hot car trunk during summer.

Delivery Across Canada (English)

Guidelines For Proper Use

What style of advice do Canadian clinicians and pharmacists give patients starting Stalevo?

Clinicians typically match the current levodopa/DDCI dose to the nearest Stalevo strength and titrate according to symptom response and tolerability.

Pharmacists counsel on timing relative to meals if patients experience nausea, interactions with other drugs and the benign urine discolouration that entacapone causes.

Shared decision-making conversations focus on the likely benefit of reduced off time versus the risk of increased dyskinesia.

Monitoring recommendations include keeping a motor diary for two to four weeks after switching and checking orthostatic blood pressure if dizziness occurs.

Liver function monitoring is advised if clinically indicated, especially in patients with pre-existing hepatic concerns given entacapone exposure.

Follow-up with neurology or a movement disorder clinic within four to twelve weeks of a switch helps assess benefit and adjust dosing.

Monitoring And Follow-Up Recommendations

Which checkpoints should patients and clinicians use after starting or adjusting Stalevo?

Maintain a motor diary noting times of on/off periods and any dyskinesia to guide titration decisions at follow-up visits.

Report new or worsening psychiatric symptoms, severe nausea, marked postural dizziness, rapid involuntary movements or signs of liver dysfunction immediately.

Schedule a medication review with a pharmacist within one to two weeks of switching and a neurology follow-up within four to twelve weeks.

Regular blood pressure checks while standing and sitting can identify orthostatic hypotension early.

For patients with hepatic impairment, consider baseline and periodic liver testing as clinically indicated.

Final Notes

Stalevo is a useful option for adults with Parkinson’s disease experiencing motor fluctuations despite levodopa/DDCI therapy.

Every tablet contains 200 mg entacapone with variable levodopa/carbidopa strengths to match prior regimens and simplify dosing.

Patients should always verify DINs on dispensed packs and confirm provincial coverage or special-authority requirements with their prescriber and pharmacist.

For timely access, call ahead to national chains or use a licensed Canadian online pharmacy that clearly explains prescription verification and DIN matching.

If uncertain about switching or side-effect management, consult a neurologist or movement disorder clinic for individualized advice.